Fingerprint
Dive into the research topics of 'A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically